BioNTech SE / Analyst ratings
Price targets
Analyst ratings
4 analysts rated this company in the past 90 days. The average target price is €116.12, this is a change of +29.3% compared to the current price.
-
UBS leaves Biontech at 'Neutral' - target $115
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Neutral" rating on BioNTech with a price target of USD 115. Growth prospects for Comirnaty are limited given stabilizing global coronavirus vaccination rates and the continued uncertainty of the political outlook for mRNA vaccines, David Dai wrote in an assessment released Friday. In addition, the oncology pipeline is still in an early development phase: For the key active ingredient BNT327, the decisive clinical data are expected in one year at the earliest./rob/gl/edh
Publication of the original study: August 21, 2025 / 7:54 p.m. / GMT First dissemination of the original study: August 21, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Biontech's 'Buy' rating
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research maintained its "Buy" rating for BioNTech after the company's earnings release, with a price target of $140. The pharmaceutical company, known for its Covid vaccine, had an uneventful second quarter, Emmanuel Papadakis wrote in a review released Tuesday. Revenue and operating profit (EBIT) were positively surprising./la/edh
Publication of the original study: August 5, 2025 / Time not specified in the study / CET. First distribution of the original study: August 5, 2025 / 7:57 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS leaves Biontech at 'Neutral' - target $115
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for BioNTech at "Neutral" with a price target of USD 115 following second-quarter results. Analyst Eliana Merle identified risks for the vaccine manufacturer's anti-COVID products in a study published Tuesday. However, the focus is increasingly on cancer treatments./rob/bek/mis
Publication of the original study: August 4, 2025 / 6:42 PM / GMT
First distribution of the original study: August 4, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $151
NEW YORK (dpa-AFX Analyser) - Research firm Jefferies has maintained its "Buy" rating for BioNTech after the company's earnings release, with a price target of $151. The vaccine manufacturer exceeded consensus estimates with its second-quarter revenue, Akash Tewari wrote in a study released Tuesday. The recently announced collaboration with Bristol-Meyers Squibb also provides BioNTech with the opportunity and resources to conduct multiple combination studies with the antibody candidate BNT327 in various indications. This supports his thesis for the stock upgrade last year./rob/ck/bek
Publication of the original study: August 4, 2025 / 4:04 PM / Time zone not specified in the study
First distribution of the original study: August 4, 2025 / 4:04 PM / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $140
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for BioNTech on the planned acquisition of competitor CureVac, with a price target of $140. In his reaction on Friday, Emmanuel Papadakis assessed the proposed transaction as overall neutral for BioNTech and a clear positive for CureVac. The Tübingen-based mRNA specialist struggled to remain relevant before and after the coronavirus pandemic./edh/ag
Publication of the original study: June 13, 2025 / Time not specified in the study / CET
First distribution of the original study: June 13, 2025 / 8:13 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $140
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for BioNTech, with a price target of $140, in light of a partnership with Bristol-Myers Squibb. Analyst Emmanuel Papadakis wrote in his commentary published Tuesday that the mRNA specialist surprised him with a large-scale collaboration. It revolves around the cancer antibody BNT327, which is becoming increasingly important for the investment story. He stated that he was generally fine with such steps, but given BioNTech's capital situation, he would have preferred to continue to pursue the development independently./tih/ag
Publication of the original study: June 3, 2025 / Time not specified in the study / CET
First distribution of the original study: June 3, 2025 / 7:50 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for BioNTech to $151 - 'Buy'
NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has raised its price target for BioNTech from $149 to $151 in light of the multi-billion dollar collaboration with Bristol-Myers, maintaining its "Buy" rating. The German mRNA specialist's oncology deal with the US pharmaceutical company gives the Mainz-based company the opportunity and resources to conduct multiple combination studies in various indications, Akash Tewari wrote on Monday. He believes this is the key to future success in this area and an important part of his positive assessment of BioNTech./edh/ag
Publication of the original study: June 2, 2025 / 6:41 PM / ET
First distribution of the original study: June 2, 2025 / 6:41 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg raises target for BioNTech to $150 - 'Buy'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has raised its price target for BioNTech from $130 to $150 in light of the multi-billion dollar collaboration with Bristol-Myers, maintaining its "Buy" rating. Harry Gillis described the vaccine manufacturer's oncology collaboration with the US pharmaceutical company as an excellent partnership deal on Monday afternoon. The expert raised its earnings forecasts (EBIT) for 2026 and 2027./rob/edh/ag
Publication of the original study: June 2, 2025 / 4:39 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Biontech's 'Buy' rating - target $130
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for BioNTech at "Buy" with a price target of $130 in light of a partnership with pharmaceutical company Bristol-Myers Squibb. The Mainz-based company, known for its coronavirus vaccine, has secured highly favorable terms, Harry Gillis wrote in a study published Monday. The partnership is no surprise and makes strategic sense, as the oncology sector is extremely competitive. With Bristol, there is now an established partner with the right infrastructure to accelerate various third-phase studies in parallel./tih/mis
Publication of the original study: June 2, 2025 / 1:37 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $149
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has maintained Biontech's "Buy" rating with a price target of 149 US dollars. The recently adjusted regulatory framework of the US Food and Drug Administration (FDA) regarding coronavirus vaccines should not have a significant impact on the related sales expectations for the company and its partner Pfizer, Akash Tewari wrote in an assessment published Tuesday.
Publication of the original study: May 20, 2025 / 1:21 PM / ET. First distribution of the original study: May 20, 2025 / 1:21 PM / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $140
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for BioNTech following first-quarter results, with a price target of $140. The vaccine specialist continues to focus on potential in the oncology sector, Emmanuel Papadakis wrote in a study released Tuesday. The results themselves would therefore have offered little news value./tih/mis
Publication of the original study: May 13, 2025 / Time not specified in the study / CET
First distribution of the original study: May 13, 2025 / 8:00 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS leaves Biontech at 'Neutral' - target $115
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for BioNTech at "Neutral" after its first-quarter results, with a price target of $115. There were few surprises, Eliana Merle wrote in a study released Wednesday. The drug developer is expected to generate revenue in the last three to four months of the year. The development of anti-cancer drugs provides the share price with long-term upside potential./rob/bek/gl
Publication of the original study: May 6, 2025 / 5:22 a.m. / GMT. First distribution of the original study: May 6, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Biontech's 'Buy' rating - target $130
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for BioNTech with a price target of $130. Analyst Harry Gillis recommended buying the shares in a study released Tuesday ahead of the release of new trial data on the immunotherapy BNT327. These, as well as individualized antibody therapies for cancer, have positive risk-reward profiles./bek/gl
Publication of the original study: May 6, 2025 / 8:53 a.m. / GMT. First distribution of the original study: May 6, 2025 / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $149
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for BioNTech following its quarterly results, with a price target of $149. Sales were lower than market expectations, wrote analyst Akash Tewari in an initial reaction released Monday. However, the vaccine manufacturer's earnings (EPS) exceeded the consensus estimate./edh/he
Publication of the original study: May 5, 2025 / 2:17 p.m. / ET First distribution of the original study: May 5, 2025 / 2:17 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $140
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for BioNTech with a price target of $140. Following the positive Harmoni-6 study by Akeso and Summit in lung cancer patients, the results of the Harmoni-2 study are less impressive, wrote analyst Emmanuel Papadakis in his commentary published on Tuesday. Nevertheless, he remains optimistic about the drug approach, which BioNTech is also pursuing with its antibody candidate BNT327./edh/ag
Publication of the original study: April 29, 2025 / Time not specified in the study / CEST
First distribution of the original study: April 29, 2025 / 8:01 a.m. / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $149
NEW YORK (dpa-AFX Analyser) - The research firm Jefferies has maintained its "Buy" rating for BioNTech with a price target of $149. Safety data for the antibody BNT327 were better than expected, wrote analyst Akash Tewari in a study released Monday. Overall, antibody-drug combinations (ADCs) appeared to have better safety and efficacy profiles than combinations of chemotherapy regimens./bek/gl
Publication of the original study: April 28, 2025 / 12:35 AM / ET. First distribution of the original study: April 28, 2025 / 12:35 AM / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $140
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for BioNTech at "Buy" with a price target of $140. Analyst Emmanuel Papadakis reviewed the vaccine manufacturer's latest study data and prospects in a study published Wednesday./edh/bek
Publication of the original study: March 26, 2025 / Time not specified in study / CET
First distribution of the original study: March 26, 2025 / 7:58 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Biontech's 'Buy' rating - target $130
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for BioNTech with a price target of $130. The mRNA specialist's business is in "good health," wrote analyst Harry Gillis in his "annual review" published Friday./ag/edh
Publication of the original study: March 20, 2025 / 6:15 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains BioNTech's 'Buy' rating - target $136
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Biontech at "Buy" with a price target of 136 US dollars. Interim results from the study confirmed the potential of the antibody BNT327 against small cell lung cancer, wrote analyst Chris Shibutani in a commentary on Friday regarding pre-release presentations for the European Lung Cancer Congress (ELCC)./ag/edh
Publication of the original study: March 20, 2025 / 4:49 PM / EDT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research lowers BioNTech target to $140 - 'Buy'
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has lowered its price target for BioNTech from $150 to $140, but maintained its "Buy" rating. Analyst Emmanuel Papadakis wrote in a study published Friday that he has adjusted his estimates for the vaccine manufacturer to reflect the recently published quarterly figures as well as the conclusions drawn from data on the tumor antibody ivonescimab for BioNTech's antibody BNT327. He justified the lowered price target with the downward revision of assumptions for coronavirus vaccines. In general, he continues to view the stock positively, but believes investors need some patience./gl/edh
Publication of the original study: March 14, 2025 / 8:10 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman lowers BioNTech target to $136 - 'Buy'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for BioNTech from $137 to $136 and maintained its "Buy" rating. Analyst Chris Shibutani adjusted his estimates on Tuesday based on the mRNA specialist's quarterly results. The focus is now clearly on oncology studies. Initial data from B327 against small cell lung cancer are expected to be presented at the European Lung Cancer Congress (ELCC) at the end of March./ag/ck
Publication of the original study: March 11, 2025 / 8:08 a.m. / EDT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS lowers BioNTech target to $115 - 'Neutral'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS lowered its price target for BioNTech from USD 131 to USD 115 following fourth-quarter results, but maintained its rating at "Neutral." The outlook for the Covid-19 vaccine fell short of expectations, analyst Eliana Merle wrote in a study published Tuesday. The focus for 2025 will be on the oncology pipeline. It explicitly referred to the antibody BNT327, for which investors are already providing an appropriate advance./tih/edh
Publication of the original study: March 11, 2025 / 9:27 a.m. / GMT
First distribution of the original study: March 11, 2025 / 9:27 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $150
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for BioNTech at "Buy" after the company's earnings release, with a price target of $150. The fourth-quarter results were not a major event, but the outlook remains slightly below expectations, wrote analyst Emmanuel Papadakis in a report released Tuesday./tih/edh
Publication of the original report: March 11, 2025 / Time not specified in report / CET
First distribution of the original report: March 11, 2025 / 7:50 a.m. / CET
Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves BioNTech at 'Neutral' - target $120
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for BioNTech at "Neutral" with a price target of $120 following fourth-quarter results. The vaccine manufacturer's sales largely met its expectations and those of the market, analyst Jessica Fye wrote in a study released Monday. The Mainz-based company reported progress in its pipeline surrounding the antibody BNT327 and its broader product offering with a focus on cancer therapy drugs./la/bek
Publication of the original study: March 10, 2025 / 12:35 / GMT
First distribution of the original study: March 10, 2025 / 12:35 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Biontech's 'Buy' rating - target $130
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for BioNTech ahead of its earnings release, with a price target of $130. News on the development of cancer drugs is in focus, wrote analyst Harry Gillis in his outlook published on Thursday. Data on several products in mid- to late-stage development are expected over the course of the year./bek/ag
Publication of the original study: March 5, 2025 / 6:57 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan lowers BioNTech target to $120 - 'Neutral'
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan lowered its price target for BioNTech from $122 to $120 and maintained its rating at "Neutral." Its updated estimates for vaccine manufacturers BioNTech and Moderna reflect the relative stability of the US market for mRNA COVID vaccines from 2025 to 2030, analyst Jessica Fye wrote in a study released Monday. It expects a volume decline in the low to mid-single-digit percentage range each year./ck/tih
Publication of the original study: January 27, 2025 / 1:34 AM / EST
First distribution of the original study: January 27, 2025 / 1:34 AM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains BioNTech's 'Buy' rating - target $137
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for BioNTech with a price target of $137. While there are market concerns about future vaccination policies in the US, analyst Chris Shibutani wrote in a study released Wednesday. However, he is focusing more on the biotech company's product development for oncology – in this area, 2025 is likely to be rich in price drivers given the upcoming important study results./bek/tav
Publication of the original study: January 14, 2025 / 10:06 PM / EST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves BioNTech at 'Neutral' - Target $122
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for BioNTech at "Neutral" with a price target of $122 following an outlook from US vaccine partner Pfizer. Analyst Jessica Fye concludes in a study published Tuesday that the assumptions incorporated into Pfizer's targets for the Covid-19 vaccine are better than expected. However, BioNTech's focus is shifting more toward new product candidates. He particularly mentioned the antibody BNT327, which is being researched in cancer therapy./tih/men
Publication of the original study: December 17, 2024 / 12:39 PM / EST
First distribution of the original study: December 17, 2024 / 12:39 PM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers BioNTech target to $149 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has lowered its price target for BioNTech from $150 to $149, but maintained its "Buy" rating. In a study published Thursday, analyst Akash Tewari drew a generally positive conclusion on new data on the antibody BNT327./bek/gl
Publication of the original study: December 11, 2024 / 9:41 PM / ET. First distribution of the original study: December 11, 2024 / 9:41 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves BioNTech at 'Neutral' - Target $122
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for BioNTech at "Neutral" with a price target of $122. Analyst Jessica Fye drew a positive conclusion from new data on the antibody BMT327, which is intended to treat breast cancer, in a study published Wednesday./bek/gl
Publication of the original study: December 11, 2024 / 00:17 / EST. First distribution of the original study: December 11, 2024 / 00:17 / EST.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research leaves Biontech at 'Buy' - target $150
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for BioNTech at "Buy" with a price target of $150. Analyst Emmanuel Papadakis assesses the results of the breast cancer study with the antibody BNT327 as minimally positive in his commentary published on Wednesday./ag/gl
Publication of the original study: November 27, 2024 / Time not specified in study / CET First distribution of the original study: November 27, 2024 / 7:55 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains BioNTech's 'Buy' rating - target $137
NEW YORK (dpa-AFX Analyser) - The US investment bank Goldman Sachs has maintained its rating for Biontech at "Buy" with a price target of 137 US dollars. Promising overall survival (OS) study data underscore the potential of the antibody BNT327 against a specific variant of breast cancer (TNBC), wrote analyst Chris Shibutani in his commentary on Tuesday regarding pre-release presentations for the San Antonio conference./ag/la
Publication of the original study: November 26, 2024 / 7:11 a.m. / EST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $150
NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has maintained its rating for Biontech at "Buy" with a price target of 150 US dollars following current study data on the cancer antibody BNT327. The results of the breast cancer study (TNBC) support his positive assessment of BNT327, analyst Akash Tewari wrote on Tuesday./edh/ag
Publication of the original study: November 26, 2024 / 7:38 a.m. / ET
First distribution of the original study: November 26, 2024 / 7:38 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains BioNTech's 'Buy' rating - target $137
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for BioNTech with a price target of $137. Analyst Chris Shibutani wrote in his commentary published on Monday that the research and development day left a positive impression overall. The cancer antibody BNT327 has groundbreaking potential. The expert sees share price weakness caused by the vaccine business as a buying opportunity./ag/ajx
Publication of the original study: November 15, 2024 / 7:12 a.m. / EST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves BioNTech at 'Neutral' - Target $124
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for BioNTech at "Neutral" following the vaccine specialist's Innovation Day, with a price target of $124. The drug candidate BNT327 has been the focus as a core component of the oncology portfolio, wrote analyst Jessica Fye in her commentary published Friday. With the recently announced acquisition of Biotheus, BioNTech is signaling its confidence in the active ingredient./tih/ag
Publication of the original study: November 14, 2024 / 10:04 PM / EST
First distribution of the original study: November 14, 2024 / 10:11 PM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains BioNTech's 'Buy' rating - target $137
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for BioNTech with a price target of $137. With the acquisition of Chinese antibody specialist Biotheus, the company is now fully benefiting from the partnership that began with the ex-China rights to its cancer drug PM8002/BNT327, commented analyst Chris Shibutani on Thursday. He considers the move strategically sensible for BioNTech and even sees the drug as a potential challenger to the blockbuster Keytruda from the US company Merck & Co./ag/tav
Publication of the original study: November 14, 2024 / 6:21 a.m. / EST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Biontech's 'Buy' rating - target $150
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research maintained its rating for BioNTech at "Buy" with a price target of $150 following a conference call on the company's quarterly results. The vaccine manufacturer's stock remains valuable, wrote analyst Emmanuel Papadakis in a study published Tuesday./edh/mis
Publication of the original study: November 12, 2024 / Time not specified in study / CET
First distribution of the original study: November 12, 2024 / 7:59 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman upgrades Biontech to 'Buy' - target raised to $137
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has upgraded BioNTech from "Neutral" to "Buy" and raised its price target from $90 to $137. Analyst Chris Shibutani now includes BNT327 – an antibody that the Mainz-based company is testing against various solid tumors – in his buy recommendation issued on Friday. The investment story continues to shift away from the difficult-to-assess Covid vaccine market./ag/gl
Publication of the original study: November 7, 2024 / 11:21 PM / EST. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research leaves Biontech at 'Buy' - target $150
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for BioNTech at "Buy" with a price target of $150. The third quarter was rather mixed, wrote analyst Emmanuel Papadakis in his commentary on the results released Tuesday. However, research and development are positive./ag/gl
Publication of the original study: November 5, 2024 / Time not specified in study / CET First distribution of the original study: November 5, 2024 / 8:30 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Biontech's 'Buy' rating - target $150
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for BioNTech following its quarterly results, with a price target of $150. The vaccine manufacturer's key figures turned out better than expected, wrote analyst Akash Tewari in a study released Monday. However, the revenue outlook for the full year 2024 has darkened./edh/he
Publication of the original study: November 4, 2024 / 10:44 AM / ET First distribution of the original study: November 4, 2024 / 10:44 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS leaves Biontech at 'Neutral' - Target $131
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for BioNTech at "Neutral" with a price target of USD 131. Artificial intelligence-based applications are promising, but rather a long-term issue, wrote analyst Eliana Merle in her commentary on the vaccine manufacturer's shares published Wednesday./ag/la
Publication of the original study: October 2, 2024 / 2:08 a.m. / GMT First distribution of the original study: October 2, 2024 / 2:08 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank raises target for BioNTech to $150 - 'Buy'
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research raised its price target for BioNTech from $95 to $150 and maintained its "Buy" rating. Analyst Emmanuel Papadakis wrote in a study published Thursday that so-called bispecific drugs received increased attention at the European Cancer Congress. The data presented by BioNTech in this regard remain relatively encouraging. The expert increased his estimate for peak sales of these active ingredients./la/tih
Publication of the original study: September 19, 2024 / Time not specified in the study / CET. First distribution of the original study: September 19, 2024 / 8:08 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies upgrades Biontech to 'Buy' - target raised to $150
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has upgraded BioNTech from "Hold" to "Buy" and raised its price target from $96 to $150. The antibody from Mainz-based company BNT327 could also be a massive sales driver, wrote analyst Akash Tewari in his commentary published Tuesday on encouraging trial data from Summit Therapeutics with a comparable approach to cancer. So far, BNT327 has shown comparable efficacy to Summit's ivonescimab. BioNTech also has sufficient cash resources to advance other drug candidates in parallel./ag/zb
Publication of the original study: September 17, 2024 / 12:04 AM / ET
First distribution of the original study: September 17, 2024 / 12:04 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan upgrades Biontech to 'Neutral' - target raised to $125
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has upgraded BioNTech from "Underweight" to "Neutral" and raised its price target from $91 to $125. Following several study results at the ESMO conference, analyst Jessica Fye expressed particular interest in the antibody BNT327 in her commentary published on Monday. Like Moderna, BioNTech needs to broaden its portfolio beyond COVID-19 vaccines, the expert said. With the cancer antibody BNT327, this could be achieved in the second half of the decade./ag/la
Publication of the original study: September 16, 2024 / 5:39 a.m. / EDT First distribution of the original study: September 16, 2024 / 5:39 a.m. / EDT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for BioNTech to $96 - 'Hold'
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies raised its price target for BioNTech from $90 to $96, but maintained its "Hold" rating. Analyst Akash Tewari wrote this in his comments on a conference call on Friday about the cancer antibody BNT327. BioNTech sees Summit Therapeutics' recent positive study data on ivonescimab as a "real signal" for BNT327 as well. Further Phase II trials are underway or about to begin./ag/tih
Publication of the original study: September 13, 2024 / 2:26 a.m. / ET
First distribution of the original study: September 13, 2024 / 5:00 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains BioNTech's 'Underweight' rating - target $91
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for BioNTech at "Underweight" with a price target of $91. Analyst Jessica Fye focused on summaries of the study data for the drug candidates that BioNTech will present on Monday ahead of the European Cancer Research Conference (ESMO). The antibody BNT327 is likely to attract the most attention with news from several tumor studies./ag/tih
Publication of the original study: September 9, 2024 / 1:06 PM / BST
First distribution of the original study: September 9, 2024 / 1:06 PM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.